Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 12Carcinoma, Hepatocellular 11Carcinoma, Non-Small-Cell Lung 9Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 8Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasm Metastasis 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Cholangiocarcinoma 3Solid Tumor 2Recurrence 2Lymphoma 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Upper Tract Urinary Carcinoma 1Thyroid Neoplasms 1Thymic epithelial tumor 1

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Tumors × toripalimab × Clear all
NCT05061628 2021-09-29

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Unknown
176 enrolled

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡